

CITATION REPORT

List of articles citing

Effect of CYP3A Inhibition and Induction on the Pharmacokinetics of Suvorexant: Two Phase I, Open-Label, Fixed-Sequence Trials in Healthy Subjects

DOI: 10.1007/s40261-019-00764-x
Clinical Drug Investigation, 2019, 39, 441-451.

Source: <https://exaly.com/paper-pdf/73745649/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
8	Sedatives and hypnotics. <i>Side Effects of Drugs Annual</i> , 2020 , 42, 67-79	0.2	1
7	Model-Based Comparative Analysis of Rifampicin and Rifabutin Drug-Drug Interaction Profile. <i>Antimicrobial Agents and Chemotherapy</i> , 2021 , 65, e0104321	5.9	6
6	Orexin Receptor Antagonists and Insomnia.		1
5	Targeting Orexin Receptors for the Treatment of Insomnia: From Physiological Mechanisms to Current Clinical Evidence and Recommendations. Volume 15, 17-38		0
4	Suvorexant, a Novel Dual Orexin Receptor Antagonist, for the Management of Insomnia. 2022 , 10,		0
3	CYP3A4 Catalyzes the Rearrangement of the Dual Orexin Receptor Antagonist Daridorexant to 4-Hydroxypiperidinol Metabolites.		1
2	The Metabolism of the Dual Orexin Receptor Antagonist Daridorexant. 1-37		0
1	The orexin story and orexin receptor antagonists for the treatment of insomnia.		0